Related Experiment Video

Updated: May 8, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

[New drugs for small animals in 2012]

I U Emmerich1

  • 1Dr. Ilka Ute Emmerich, VETIDATA, Institut für Pharmakologie, Pharmazie und Toxikologie, Veterinärmedizinische Fakultät der Universität Leipzig, An den Tierkliniken 39, 04103 Leipzig,

Tierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
|August 21, 2013
PubMed

More Related Videos

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model05:09

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...